MedTrace Logo

Handwriting as an Objective Tool to Support the Identification of People With Alzheimer's Disease

NCT06483438 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2024-08-09

No results posted yet for this study

Summary

Alzheimer's disease (AD) is the most common of dementia, and has associated cognitive and motor disorders, with consequences on daily activities, including handwriting.

Handwriting has been used to study fine motor control or executive functioning in healthy and unhealthy populations. Changes in this skill are present at different stages of the clinical course of Alzheimer's Disease. The sensorimotor deterioration is observed in handwriting tasks (motion kinematics, such as movement time, speed, and profiles) and brain activity rhythms.

Handwriting has been used to study fine motor control or executive functioning in healthy and unhealthy populations, and changes in this skill are present at different stages of the clinical course of dementia. From a theoretical perspective, because sensorimotor deterioration observed in handwriting tasks (motion kinematics, such as movement time, speed, and profiles).

Due to the large number of brain areas related to handwriting performance, brain electrical activity analysis can be an early indicator of brain dysfunction. Although there is a lack of validation across healthy and non-healthy populations Electroencephalogram (EEG) measures have the potential for evaluating cognitive performance.

This research aims to analyze the suitability of the handwriting assessment protocol, which can contribute to a more in-depth knowledge of this subject and potentially support early identification and treatment.

Conditions

Sponsors & Collaborators

  • NOVA Medical School

    collaborator OTHER

  • Faculdade de Motricidade Humana

    collaborator OTHER

  • University of Lisbon

    collaborator OTHER

  • University of Évora

    lead OTHER

Principal Investigators

  • Ana Matias, PhD · University of Évora

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-02
Primary Completion
2024-07-30
Completion
2024-07-30

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06483438 on ClinicalTrials.gov